신경 진단 시장 : 시장 인사이트, 경쟁 구도, 시장 예측(2034년)

Neurodiagnostics Market Summary

• The global neurodiagnostics market is expected to increase from USD 9,910.93 million in 2025 to USD 18,598.04 million by 2034, reflecting strong and sustained growth.
• The global neurodiagnostics market is growing at a CAGR of 7.31% during the forecast period from 2026 to 2034.
• The neurodiagnostics market is being collectively driven by the rising prevalence of neurological disorders such as Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which is significantly increasing the need for accurate and continuous brain monitoring solutions. At the same time, the expansion of sleep disorder diagnosis, particularly for conditions like Sleep Apnea, is boosting the demand for polysomnography and home-based diagnostic systems. Additionally, the growing number of complex neurosurgical procedures is driving the adoption of intraoperative neurophysiological monitoring to ensure patient safety and surgical precision. These demand-side factors are further amplified by rapid technological advancements such as AI-enabled EEG analysis, portable devices, and cloud-based platforms, which are improving diagnostic efficiency, accessibility, and accuracy. Together, these trends are creating a strong, multi-dimensional growth environment for the global neurodiagnostics market.
• The leading companies operating in the neurodiagnostics market include Natus Medical Incorporated, Nihon Kohden Corporation, Medtronic plc, Cadwell Industries, Compumedics Limited, EB Neuro S.p.A., Micromed S.p.A., Neurosoft, Deymed Diagnostic, Ambu A/S, Brain Products GmbH, Electrical Geodesics Inc. (EGI), NCC Medical Co., NeuroWave Systems, Neuroelectrics, Persyst Development Corporation, OpenBCI, Emotiv, NeuroSky, Advanced Brain Monitoring, and others.
• North America is expected to dominate the neurodiagnostics market due to its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and strong presence of leading industry players such as Natus Medical Incorporated, Nihon Kohden Corporation, and Medtronic plc. The region also has a high prevalence of neurological conditions like Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which drives consistent demand for neurodiagnostic procedures. Additionally, increasing awareness of sleep disorders such as Sleep Apnea, well-established reimbursement frameworks, and continuous investments in research and development further support market growth, reinforcing North America's leading position.
• In the product type segment of the neurodiagnostics market, the systems category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Neurodiagnostics Market

• Rising prevalence of neurological disorders leading to a surge in neurodiagnostics: The increasing incidence of neurological conditions such as Epilepsy, Parkinson's Disease, Alzheimer's Disease, and Stroke is a primary driver of the neurodiagnostics market. These conditions require continuous monitoring and early diagnosis, significantly increasing the demand for EEG, EMG, and other neurodiagnostic tests. Additionally, the growing burden of neurodegenerative diseases globally is pushing healthcare systems to adopt advanced diagnostic solutions.
• Expansion of sleep disorder diagnosis: The rising prevalence of sleep disorders such as Sleep Apnea and insomnia has increased the demand for polysomnography and home sleep testing devices. Sleep diagnostics is becoming a major sub-segment within neurodiagnostics.
• Increasing neurosurgical procedures: The growth in complex neurosurgeries and spinal procedures is driving the demand for intraoperative neurophysiological monitoring (IONM) systems. These systems help reduce surgical risks by continuously monitoring nerve function during procedures.
• Technological advancements in neurodiagnostic systems: Continuous innovations such as AI-based EEG interpretation, portable and wearable neurodiagnostic devices, cloud-based data analysis platforms, and advanced intraoperative monitoring systems are improving diagnostic accuracy, efficiency, and accessibility, and encouraging healthcare providers to adopt modern neurodiagnostic solutions.

Neurodiagnostics Market Report Segmentation

This neurodiagnostics market report offers a comprehensive overview of the global neurodiagnostics market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Systems {Electroencephalography (EEG) Systems, Electromyography (EMG) Systems, Nerve Conduction Studies (NCS) Systems, Polysomnography Systems, and Others}, Accessories and Consumables, and Software), Technology (Neuroimaging Technology, In-Vitro Diagnostic, and Neuroinformatics), Application (Epilepsy and Seizure Disorders, Sleep Disorders, Stroke and Cerebrovascular Diseases, Parkinson's, Dementia and Alzheimer's, and Others), End-Users (Hospitals & Neurology Clinics, Diagnostic Laboratories, Ambulatory Surgical Centers, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing neurodiagnostics market.

Neurodiagnostics refers to a group of medical tests and technologies used to evaluate the function and health of the nervous system, including the brain, spinal cord, and peripheral nerves. It involves techniques such as EEG, EMG, nerve conduction studies, and sleep diagnostics to detect, monitor, and manage neurological conditions like Epilepsy, Alzheimer's Disease, and Parkinson's Disease. These tools help clinicians make accurate diagnoses and guide effective treatment decisions.

The neurodiagnostics market is being collectively driven by the rising prevalence of neurological disorders such as Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which is significantly increasing the need for accurate, real-time, and continuous brain monitoring solutions across both acute and chronic care settings. As these conditions often require long-term management and repeated assessments, healthcare providers are increasingly relying on advanced neurodiagnostic tools such as EEG, EMG, and continuous monitoring systems. At the same time, the expansion of sleep disorder diagnosis, particularly for conditions like Sleep Apnea, is boosting demand for polysomnography systems as well as convenient home-based diagnostic devices, thereby widening the market scope beyond hospital settings.

Additionally, the growing number of complex neurosurgical and spinal procedures is driving the adoption of intraoperative neurophysiological monitoring (IONM) systems, which play a critical role in reducing surgical risks and improving patient outcomes by enabling real-time nerve function tracking during surgery. These demand-side drivers are further strengthened by rapid technological advancements, including AI-enabled EEG interpretation, portable and wearable neurodiagnostic devices, and cloud-based data management platforms. Such innovations are enhancing diagnostic accuracy, reducing interpretation time, and improving accessibility in remote or underserved regions. Collectively, these factors are creating a robust, multi-dimensional growth environment, positioning neurodiagnostics as a vital component of modern neurological care and a rapidly expanding global market.

What are the latest neurodiagnostics market dynamics and trends?

The neurodiagnostics market is being collectively driven by the rising prevalence of neurological disorders such as Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which is significantly increasing the need for accurate and continuous brain monitoring solutions. According to the data provided by the World Health Organization (2024), globally, an estimated 5 million people were diagnosed with epilepsy each year.

Additionally, according to the projections provided by the Alzheimer's Association (2026), more than 7 million Americans are living with Alzheimer's in 2026, and by 2050, this number is projected to rise to nearly 13 million. Epilepsy requires frequent and long-term monitoring through EEG and related technologies to detect abnormal brain activity, manage seizures, and adjust treatment plans, leading to high utilization of neurodiagnostic systems and consumables. Similarly, Alzheimer's disease is driving demand for early diagnosis and disease progression monitoring using advanced neurodiagnostic tools, as early detection is critical for improving patient outcomes and care planning. The chronic and progressive nature of both conditions results in repeated diagnostic procedures, thereby increasing the adoption of neurodiagnostic devices, software, and consumables, and ultimately contributing to sustained market growth.

Furthermore, the expansion of sleep disorder diagnosis is significantly boosting the neurodiagnostics market by increasing the demand for advanced monitoring systems such as polysomnography (PSG), EEG-based sleep analysis, and home-based diagnostic devices. The growing prevalence of sleep conditions, particularly sleep apnea, insomnia, and narcolepsy, along with rising awareness and screening initiatives, is leading to higher diagnostic volumes across hospitals, sleep labs, and home-care settings. According to the data provided by the Sleep Foundation (2025), up to 75% of older adults experienced symptoms of insomnia. Polysomnography remains the gold-standard diagnostic tool and accounts for a dominant share of sleep monitoring, while home sleep testing is rapidly expanding due to convenience and accessibility. This shift toward continuous and decentralized monitoring is directly increasing the adoption of neurodiagnostic systems and consumables. Recent company-specific developments further highlight this growth trend. In January 2026, Empatica received FDA clearance for its EmbraceMini wearable device designed for sleep monitoring and actigraphy-based assessment, enabling remote and continuous sleep diagnostics. Additionally, in June 2025, the company enhanced its digital health platform with advanced physiological monitoring capabilities, supporting sleep and neurological data integration. Thus, the factors mentioned above are expected to boost the overall market of neurodiagnostics during the forecast period.

However, the neurodiagnostics market faces significant constraints due to the combined impact of complexity in data interpretation and stringent regulatory approval processes. Neurodiagnostic tests such as EEG and EMG generate highly complex and variable brain signal data, requiring specialized expertise and time-intensive analysis, which can limit efficiency and scalability in clinical settings. At the same time, strict regulatory requirements for the approval of neurodiagnostic devices and software, especially those incorporating AI, prolong product development timelines and increase compliance costs for manufacturers. Together, these factors slow down the adoption of advanced technologies, delay market entry of innovative solutions, and act as key barriers to the overall growth of the neurodiagnostics market.

Neurodiagnostics Market Segment Analysis

Neurodiagnostics Market by Product Type (Systems {Electroencephalography (EEG) Systems, Electromyography (EMG) Systems, Nerve Conduction Studies (NCS) Systems, Polysomnography Systems, and Others}, Accessories and Consumables, and Software), Technology (Neuroimaging Technology, In-Vitro Diagnostic, and Neuroinformatics), Application (Epilepsy and Seizure Disorders, Sleep Disorders, Stroke and Cerebrovascular Diseases, Parkinson's, Dementia and Alzheimer's, and Others), End-Users (Hospitals & Neurology Clinics, Diagnostic Laboratories, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Neurodiagnostics Market Regional Analysis

North America Neurodiagnostics Market Trends

North America is expected to account for the highest proportion of 39% of the neurodiagnostics market in 2025, out of all regions. North America is expected to dominate the neurodiagnostics market due to its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and strong presence of leading industry players such as Natus Medical Incorporated, Nihon Kohden Corporation, and Medtronic plc. The region also has a high prevalence of neurological conditions like Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which drives consistent demand for neurodiagnostic procedures. Additionally, increasing awareness of sleep disorders such as Sleep Apnea, well-established reimbursement frameworks, and continuous investments in research and development further support market growth, reinforcing North America's leading position.

According to the data provided by the Centre for Disease Control and Prevention (2024), almost 3 million U.S. adults have epilepsy.

Additionally, as per the data provided by the Parkinson's Foundation (2026), Parkinson's disease affected more than 1.1 million people in the U.S. Epilepsy relies heavily on EEG and related diagnostic tools for seizure detection, classification, and treatment management, often requiring repeated and prolonged monitoring, which drives high utilization of neurodiagnostic systems and consumables. Similarly, Parkinson's disease, being a progressive neurodegenerative disorder, requires ongoing assessment of brain function and motor activity through neurophysiological tests and advanced diagnostic techniques. The chronic nature of both conditions leads to frequent follow-ups and continuous monitoring, thereby increasing the adoption of neurodiagnostic devices, software, and consumables, ultimately contributing to sustained market growth.

Additionally, the neurodiagnostics market in North America is being strongly driven by the expansion of sleep disorder diagnosis, increasing neurosurgical procedures, and rapid technological advancements in neurodiagnostic systems, collectively creating a high-growth environment across clinical and home-care settings. The rising prevalence of sleep disorders such as sleep apnea is significantly increasing the demand for polysomnography (PSG) systems and EEG-based sleep analysis, particularly with the shift toward home-based and wearable diagnostics. This is evident from recent developments, such as in March 2024, Beacon Biosignals received FDA 510(k) clearance for its SleepStageML(TM) AI-based sleep analysis software, which automates sleep staging from EEG data and improves diagnostic efficiency.

At the same time, the increasing volume of neurosurgical and spinal procedures in North America is driving the adoption of intraoperative neurophysiological monitoring (IONM) systems, which rely heavily on EEG, EMG, and evoked potential technologies to ensure surgical precision and patient safety. This demand is further amplified by continuous technological advancements, including portable and AI-integrated neurodiagnostic systems. For instance, in April 2026, the FDA granted 510(k) clearance to Zeto Inc. for its "Zeto New Wave" EEG system, designed for outpatient and home-based use with cloud connectivity and integrated multi-signal monitoring capabilities, improving accessibility and workflow efficiency.

Further supporting this trend, in September 2024, Forest Devices received FDA 510(k) approval for its SignalNED system, highlighting continued innovation in neurodiagnostic monitoring solutions across North America. Moreover, integrated neurodiagnostic platforms such as EB Neuro's BE Plus PRO and Neurotravel LIGHT systems combine EEG, EMG, and polysomnography capabilities, reflecting the growing demand for multi-functional diagnostic systems.

Collectively, the rising burden of sleep disorders, increasing surgical interventions, and a strong pipeline of FDA approvals across EEG, EMG/NCS, and polysomnography technologies are significantly accelerating the adoption of neurodiagnostic solutions in North America, thereby driving overall market growth.

Europe Neurodiagnostics Market Trend

The neurodiagnostics market in Europe is witnessing strong and sustained growth, driven by the rising prevalence of neurological disorders, an aging population, and increasing investments in advanced diagnostic technologies. Countries such as Germany, the UK, and France are experiencing a growing burden of conditions like dementia, epilepsy, and stroke, which is significantly increasing the demand for neurodiagnostic procedures such as EEG, EMG, and neuroimaging. For instance, according to the data provided by the Alzheimer's Foundation (2025), in 2025, an estimated 9,065,706 people with dementia lived in EU27 countries, and by 2050, an estimated 14,335,788 people with dementia will live in EU27 countries. Thus, there is a growing demand for neurodiagnostic technologies across the region.

Additionally, Europe benefits from well-established healthcare systems, favorable government initiatives, and expanding research funding in neuroscience, all of which are supporting the adoption of innovative diagnostic solutions. The region is also seeing increasing integration of digital technologies, including AI-based EEG analysis and portable monitoring systems, further accelerating market expansion. Recent developments further highlight this growth trajectory. In October 2025, Natus Medical Incorporated acquired Norway-based Holberg EEG to integrate AI-driven EEG interpretation technology into its portfolio, strengthening its presence in the European market and enhancing diagnostic accuracy.

Collectively, the combination of increasing disease burden, technological innovation, and strategic company activities is driving strong and sustained growth of the neurodiagnostics market across Europe.

Asia-Pacific Neurodiagnostics Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the neurodiagnostics market due to its large and rapidly aging population, rising prevalence of neurological disorders such as Epilepsy, Stroke, and Parkinson's Disease, and improving healthcare infrastructure across key countries like China, India, and Japan. Increasing healthcare expenditure, expanding access to diagnostic services, and growing awareness about early detection of neurological conditions are significantly boosting the adoption of neurodiagnostic systems such as EEG, EMG, and sleep diagnostics. Additionally, the region is witnessing a shift toward portable and cost-effective diagnostic solutions, making neurodiagnostics more accessible in both urban and semi-urban areas. Government initiatives aimed at strengthening healthcare systems, along with rising investments by global and regional players, are further accelerating market growth. Collectively, these factors are positioning APAC as the fastest-growing region in the global neurodiagnostics market.

Who are the major players in the neurodiagnostics market?

The following are the leading companies in the neurodiagnostics market. These companies collectively hold the largest market share and dictate industry trends.

• Natus Medical Incorporated
• Nihon Kohden Corporation
• Medtronic plc
• Cadwell Industries
• Compumedics Limited
• EB Neuro S.p.A.
• Micromed S.p.A.
• Neurosoft
• Deymed Diagnostic
• Ambu A/S
• Brain Products GmbH
• Electrical Geodesics Inc. (EGI)
• NCC Medical Co.
• NeuroWave Systems
• Neuroelectrics
• Persyst Development Corporation
• OpenBCI
• Emotiv
• NeuroSky
• Advanced Brain Monitoring
• Others

How is the competitive landscape shaping the neurodiagnostics market?

The competitive landscape of the neurodiagnostics market is highly dynamic and moderately consolidated, characterized by the presence of large global players alongside emerging technology-focused companies. Major companies such as Siemens Healthineers, GE HealthCare, Philips, and Natus Medical dominate the market by leveraging strong product portfolios in neuroimaging, EEG/EMG systems, and integrated diagnostic platforms. These players are increasingly focusing on technological innovation, particularly AI integration, cloud-based analytics, and portable diagnostic solutions, to differentiate their offerings and enhance clinical efficiency. At the same time, the market is witnessing intensifying competition through mergers, acquisitions, and strategic partnerships, as companies aim to expand their technological capabilities and geographic presence.

Additionally, the rise of start-ups and niche players specializing in AI-driven neurodiagnostic software, biomarker-based diagnostics, and wearable devices is disrupting the traditional device-centric market, pushing established companies to shift toward integrated, service-based models that combine hardware, software, and ana This evolving competition is further shaped by continuous product launches, regulatory approvals, and R&D investments, leading to rapid innovation and improved diagnostic accuracy. Overall, the competitive landscape is moving toward a technology-driven, partnership-oriented ecosystem, where companies compete not only on products but also on digital capabilities, clinical outcomes, and long-term value delivery.

Recent Developmental Activities in the Neurodiagnostics Market

• In April 2026, the FDA granted 510(k) clearance to Zeto Inc. for its "Zeto New Wave" EEG system, designed for outpatient and home-based use with cloud connectivity and integrated multi-signal monitoring capabilities, improving accessibility and workflow efficiency.
• In January 2026, Empatica received FDA clearance for its EmbraceMini wearable device designed for sleep monitoring and actigraphy-based assessment, enabling remote and continuous sleep diagnostics.

Neurodiagnostics Market Segmentation

• Neurodiagnostics by Product Type Exposure
• System
• Electroencephalography (EEG) Systems
• Electromyography (EMG) Systems
• Nerve Conduction Studies (NCS) Systems
• Polysomnography Systems
• Others
• Accessories & Consumables
• Software
• Neurodiagnostics Technology Exposure
• Neuroimaging Technology
• In-Vitro Diagnostic
• Neuroinformatics
• Neurodiagnostics Application Exposure
• Epilepsy and Seizure Disorders
• Sleep Disorders
• Stroke and Cerebrovascular Diseases
• Parkinson's
• Dementia and Alzheimer's
• Others
• Neurodiagnostics End-Users Exposure
• Hospitals & Neurology Clinics
• Diagnostic Laboratories
• Ambulatory Surgical Centers
• Others
• Neurodiagnostics Geography Exposure
• North America Neurodiagnostics Market
• United States Neurodiagnostics Market
• Canada Neurodiagnostics Market
• Mexico Neurodiagnostics Market
• Europe Neurodiagnostics Market
• United Kingdom Neurodiagnostics Market
• Germany Neurodiagnostics Market
• France Neurodiagnostics Market
• Italy Neurodiagnostics Market
• Spain Neurodiagnostics Market
• Rest of Europe Neurodiagnostics Market
• Asia-Pacific Neurodiagnostics Market
• China Neurodiagnostics Market
• Japan Neurodiagnostics Market
• India Neurodiagnostics Market
• Australia Neurodiagnostics Market
• South Korea Neurodiagnostics Market
• Rest of Asia-Pacific Neurodiagnostics Market
• Rest of the World Neurodiagnostics Market
• South America Neurodiagnostics Market
• Middle East Neurodiagnostics Market
• Africa Neurodiagnostics Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are transforming neurodiagnostics by enabling faster, more accurate, and scalable analysis of complex neurological data. Advanced machine learning algorithms are increasingly used to interpret EEG and EMG signals, allowing automated detection of abnormalities such as seizures in Epilepsy and early cognitive decline associated with Alzheimer's Disease. AI is also being integrated into sleep diagnostics to automate sleep stage scoring and identify disorders like Sleep Apnea, significantly reducing manual workload and improving consistency. In addition, AI-driven neuroimaging tools enhance the detection of structural and functional brain changes, supporting early diagnosis of conditions such as Stroke and neurodegenerative diseases. These technologies are further enabling real-time monitoring, predictive analytics, and personalized treatment planning by analyzing large datasets through cloud-based platforms. Overall, AI is shifting neurodiagnostics toward a more automated, precise, and patient-centric approach, improving clinical outcomes while increasing efficiency across healthcare systems.

U.S. Tariff Impact Analysis on Neurodiagnostics Market:

The U.S. tariff impact on the neurodiagnostics market, as part of the broader medical device industry, has been significant and largely restrictive, influencing costs, supply chains, and market dynamics. Recent tariff policies, including the April 2025 U.S. tariff overhaul, introduced a baseline ~10% import duty on most medical devices, with higher country-specific tariffs (e.g., up to 20%-50%+ for key trading partners), marking a shift from the historically low-duty environment for medtech products. Since a large proportion of neurodiagnostic equipment (such as EEG, EMG, and imaging components) and consumables are imported, these tariffs have increased procurement and manufacturing costs, putting pressure on margins for companies and raising prices for healthcare providers.

Additionally, tariffs are disrupting global supply chains, as many neurodiagnostic systems rely on internationally sourced components such as semiconductors and sensors, leading to delays in production and product availability. This has forced manufacturers to reconsider sourcing strategies, shift toward localized production, or absorb higher costs, impacting overall market growth. Furthermore, higher costs are often passed on to hospitals, potentially delaying equipment upgrades and reducing adoption rates of advanced neurodiagnostic technologies.

However, on the positive side, U.S. tariffs are also encouraging domestic manufacturing and supply chain localization, which may strengthen long-term resilience and reduce dependency on imports. Overall, while tariffs are creating short-term challenges such as cost inflation, supply disruptions, and slowed adoption, they are simultaneously reshaping the competitive landscape and operational strategies within the U.S. neurodiagnostics market.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the neurodiagnostics market report study

• Market size analysis for the current neurodiagnostics market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the neurodiagnostics market.
• Various opportunities available for the other competitors in the neurodiagnostics market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current neurodiagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the neurodiagnostics market growth in the future.

Frequently Asked Questions for the Neurodiagnostics Market

1. What is the growth rate of the neurodiagnostics market?

• The neurodiagnostics market is estimated to grow at a CAGR of 7.31% during the forecast period from 2026 to 2034.

2. What is the market for neurodiagnostics?

• The global neurodiagnostics market is expected to increase from USD 9,910.93 million in 2025 to USD 18,598.04 million by 2034.

3. Which region has the highest share in the neurodiagnostics market?

• North America is expected to dominate the neurodiagnostics market due to its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and strong presence of leading industry players such as Natus Medical Incorporated, Nihon Kohden Corporation, and Medtronic plc. The region also has a high prevalence of neurological conditions like Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which drives consistent demand for neurodiagnostic procedures. Additionally, increasing awareness of sleep disorders such as Sleep Apnea, well-established reimbursement frameworks, and continuous investments in research and development further support market growth, reinforcing North America's leading position.

4. What are the drivers for the neurodiagnostics market?

• The neurodiagnostics market is being collectively driven by the rising prevalence of neurological disorders such as Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which is significantly increasing the need for accurate and continuous brain monitoring solutions. At the same time, the expansion of sleep disorder diagnosis, particularly for conditions like Sleep Apnea, is boosting the demand for polysomnography and home-based diagnostic systems. Additionally, the growing number of complex neurosurgical procedures is driving the adoption of intraoperative neurophysiological monitoring to ensure patient safety and surgical precision. These demand-side factors are further amplified by rapid technological advancements such as AI-enabled EEG analysis, portable devices, and cloud-based platforms, which are improving diagnostic efficiency, accessibility, and accuracy. Together, these trends are creating a strong, multi-dimensional growth environment for the global neurodiagnostics market.

5. Who are the key players operating in the neurodiagnostics market?

• Some of the key market players operating in the neurodiagnostics market include Natus Medical Incorporated, Nihon Kohden Corporation, Medtronic plc, Cadwell Industries, Compumedics Limited, EB Neuro S.p.A., Micromed S.p.A., Neurosoft, Deymed Diagnostic, Ambu A/S, Brain Products GmbH, Electrical Geodesics Inc. (EGI), NCC Medical Co., NeuroWave Systems, Neuroelectrics, Persyst Development Corporation, OpenBCI, Emotiv, NeuroSky, Advanced Brain Monitoring, and others.

Table of Contents

1. Neurodiagnostics Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Neurodiagnostics Market Executive Summary

• 2.1 Market at Glance

3. Neurodiagnostics Market Key Factors Analysis

• 3.1 Neurodiagnostics Market Drivers
  • 3.1.1 Rising prevalence of neurological disorders
  • 3.1.2 Expansion of sleep disorder diagnosis
  • 3.1.3 Increasing neurosurgical procedures
  • 3.1.4 Technological advancements in neurodiagnostic systems
• 3.2 Neurodiagnostics Market Restraints and Challenges
  • 3.2.1 Complexity in data interpretation
  • 3.2.2 Stringent regulatory process for product approval
• 3.3 Neurodiagnostics Market Opportunity
  • 3.3.1 Growing adoption of artificial intelligence for automated EEG interpretation, predictive analytics, and early detection of neurological conditions

4. Impact Analysis

• 4.1 AI-Powered Innovations and Applications
• 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

• 5.1 The United States
• 5.2 Europe
• 5.3 Japan
• 5.4 China

6. Neurodiagnostics Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Neurodiagnostics Market Assessment

• 7.1 By Product Type
  • 7.1.1 System
    • 7.1.1.1 Electroencephalography (EEG) Systems
    • 7.1.1.2 Electromyography (EMG) Systems
    • 7.1.1.3 Nerve Conduction Studies (NCS) Systems
    • 7.1.1.4 Polysomnography Systems
    • 7.1.1.5 Others
  • 7.1.2 Accessories & Consumables
  • 7.1.3 Software
• 7.2 By Technology
  • 7.2.1 Neuroimaging Technology
  • 7.2.2 In-Vitro Diagnostic
  • 7.2.3 Neuroinformatics
• 7.3 By Application
  • 7.3.1 Epilepsy and Seizure Disorders
  • 7.3.2 Sleep Disorders
  • 7.3.3 Stroke and Cerebrovascular Diseases
  • 7.3.4 Parkinson's
  • 7.3.5 Dementia and Alzheimer's
  • 7.3.6 Others
• 7.4 By End-Users
  • 7.4.1 Hospitals & Neurology Clinics
  • 7.4.2 Diagnostic Laboratories
  • 7.4.3 Ambulatory Surgical Centers
  • 7.4.4 Others
• 7.5 By Geography
  • 7.5.1 North America
    • 7.5.1.1 United States Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.1.2 Canada Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.1.3 Mexico Neurodiagnostics Market Size in USD million (2023-2034)
  • 7.5.2 Europe
    • 7.5.2.1 France Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.2.2 Germany Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.2.3 United Kingdom Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.2.4 Italy Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.2.5 Spain Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.2.6 Rest of Europe Neurodiagnostics Market Size in USD million (2023-2034)
  • 7.5.3 Asia-Pacific
    • 7.5.3.1 China Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.3.2 Japan Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.3.3 India Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.3.4 Australia Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.3.5 South Korea Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.3.6 Rest of Asia-Pacific Neurodiagnostics Market Size in USD million (2023-2034)
  • 7.5.4 Rest of the World (RoW)
    • 7.5.4.1 Middle East Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.4.2 Africa Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.4.3 South America Neurodiagnostics Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Neurodiagnostics Market Company and Product Profiles

• 10.1 Natus Medical Incorporated
  • 10.1.1 Company Overview
  • 10.1.2 Company Snapshot
  • 10.1.3 Financial Overview
  • 10.1.4 Product Listing
  • 10.1.5 Entropy
• 10.2 Nihon Kohden Corporation
  • 10.2.1 Company Overview
  • 10.2.2 Company Snapshot
  • 10.2.3 Financial Overview
  • 10.2.4 Product Listing
  • 10.2.5 Entropy
• 10.3 Medtronic plc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Snapshot
  • 10.3.3 Financial Overview
  • 10.3.4 Product Listing
  • 10.3.5 Entropy
• 10.4 Cadwell Industries
  • 10.4.1 Company Overview
  • 10.4.2 Company Snapshot
  • 10.4.3 Financial Overview
  • 10.4.4 Product Listing
  • 10.4.5 Entropy
• 10.5 Compumedics Limited
  • 10.5.1 Company Overview
  • 10.5.2 Company Snapshot
  • 10.5.3 Financial Overview
  • 10.5.4 Product Listing
  • 10.5.5 Entropy
• 10.6 EB Neuro S.p.A.
  • 10.6.1 Company Overview
  • 10.6.2 Company Snapshot
  • 10.6.3 Financial Overview
  • 10.6.4 Product Listing
  • 10.6.5 Entropy
• 10.7 Micromed S.p.A.
  • 10.7.1 Company Overview
  • 10.7.2 Company Snapshot
  • 10.7.3 Financial Overview
  • 10.7.4 Product Listing
  • 10.7.5 Entropy
• 10.8 Neurosoft
  • 10.8.1 Company Overview
  • 10.8.2 Company Snapshot
  • 10.8.3 Financial Overview
  • 10.8.4 Product Listing
  • 10.8.5 Entropy
• 10.9 Deymed Diagnostic
  • 10.9.1 Company Overview
  • 10.9.2 Company Snapshot
  • 10.9.3 Financial Overview
  • 10.9.4 Product Listing
  • 10.9.5 Entropy
• 10.10 Ambu A/S
  • 10.10.1 Company Overview
  • 10.10.2 Company Snapshot
  • 10.10.3 Financial Overview
  • 10.10.4 Product Listing
  • 10.10.5 Entropy
• 10.11 Brain Products GmbH
  • 10.11.1 Company Overview
  • 10.11.2 Company Snapshot
  • 10.11.3 Financial Overview
  • 10.11.4 Product Listing
  • 10.11.5 Entropy
• 10.12 Electrical Geodesics Inc. (EGI)
  • 10.12.1 Company Overview
  • 10.12.2 Company Snapshot
  • 10.12.3 Financial Overview
  • 10.12.4 Product Listing
  • 10.12.5 Entropy
• 10.13 NCC Medical Co.
  • 10.13.1 Company Overview
  • 10.13.2 Company Snapshot
  • 10.13.3 Financial Overview
  • 10.13.4 Product Listing
  • 10.13.5 Entropy
• 10.14 NeuroWave Systems
  • 10.14.1 Company Overview
  • 10.14.2 Company Snapshot
  • 10.14.3 Financial Overview
  • 10.14.4 Product Listing
  • 10.14.5 Entropy
• 10.15 Neuroelectrics
  • 10.15.1 Company Overview
  • 10.15.2 Company Snapshot
  • 10.15.3 Financial Overview
  • 10.15.4 Product Listing
  • 10.15.5 Entropy
• 10.16 Persyst Development Corporation
  • 10.16.1 Company Overview
  • 10.16.2 Company Snapshot
  • 10.16.3 Financial Overview
  • 10.16.4 Product Listing
  • 10.16.5 Entropy
• 10.17 OpenBCI
  • 10.17.1 Company Overview
  • 10.17.2 Company Snapshot
  • 10.17.3 Financial Overview
  • 10.17.4 Product Listing
  • 10.17.5 Entropy
• 10.18 Emotiv
  • 10.18.1 Company Overview
  • 10.18.2 Company Snapshot
  • 10.18.3 Financial Overview
  • 10.18.4 Product Listing
  • 10.18.5 Entropy
• 10.19 NeuroSky
  • 10.19.1 Company Overview
  • 10.19.2 Company Snapshot
  • 10.19.3 Financial Overview
  • 10.19.4 Product Listing
  • 10.19.5 Entropy
• 10.20 Advanced Brain Monitoring
  • 10.20.1 Company Overview
  • 10.20.2 Company Snapshot
  • 10.20.3 Financial Overview
  • 10.20.4 Product Listing
  • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us